Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Leukemia

Free Subscription Articles published in Int J Hematol Retrieve available abstracts of 280 articles: HTML format

Single Articles

July 2021
1. SATOH T, Kayano H, Watanabe A, Ohta A, et al
   Lethal macrophage-related complications of juvenile myelomonocytic leukemia with a blastic crisis: an autopsy case report.
   Int J Hematol. 2021 Jul 16. pii: 10.1007/s12185-021-03189.
   PubMed     Abstract available
   
   
   June 2021
2. LV K, Cai C, Chen J, Xu M, et al
   Prognostic value of lymphoid marker CD7 expression in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in first morphological complete remission.
   Int J Hematol. 2021 Jun 26. pii: 10.1007/s12185-021-03182.
   PubMed     Abstract available
   
   
   
3. MORI T, Kikuchi T, Yamazaki R, Koda Y, et al
   Phase 1 study of plerixafor in combination with total body irradiation-based myeloablative conditioning for allogeneic hematopoietic stem cell transplantation.
   Int J Hematol. 2021;113:877-883.
   PubMed     Abstract available
   
   
   May 2021
4. ARAKAWA Y, Masutani S, Oshima K, Mitani Y, et al
   Asian population may have a lower incidence of hip osteonecrosis in childhood acute lymphoblastic leukemia.
   Int J Hematol. 2021 May 18. pii: 10.1007/s12185-021-03163.
   PubMed     Abstract available
   
   
   
5. MORITA K, Sasaki K
   Current status and novel strategy of CML.
   Int J Hematol. 2021;113:624-631.
   PubMed     Abstract available
   
   
   
6. KIMURA S
   Evolution of CML treatment.
   Int J Hematol. 2021;113:622-623.
   PubMed    
   
   
   
7. SHAN M, Lu Y, Yang M, Wang P, et al
   Characteristics and transplant outcome of myeloid sarcoma: a single-institute study.
   Int J Hematol. 2021;113:682-692.
   PubMed     Abstract available
   
   
   April 2021
8. KIDOGUCHI K, Ureshino H, Kizuka-Sano H, Yamaguchi K, et al
   Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
   Int J Hematol. 2021 Apr 27. pii: 10.1007/s12185-021-03156.
   PubMed     Abstract available
   
   
   
9. CHUAH C, Koh LP, Numbenjapon T, Zang DY, et al
   Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
   Int J Hematol. 2021 Apr 13. pii: 10.1007/s12185-021-03144.
   PubMed     Abstract available
   
   
   
10. KOBAYASHI T, Ubukawa K, Fujishima M, Takahashi N, et al
    Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis.
    Int J Hematol. 2021;113:600-605.
    PubMed     Abstract available
    
    
    March 2021
11. KONDO H, Kanayama T, Matsumura U, Urata T, et al
    Relapsed RUNX1-RUNX1T1-positive acute myeloid leukemia with pseudo-Chediak-Higashi granules.
    Int J Hematol. 2021 Mar 29. pii: 10.1007/s12185-021-03141.
    PubMed    
    
    
    
12. BNAYA A, Ruchlemer R, Itzkowitz E, Gabbay E, et al
    Incidence, risk factors, and recognition of pseudohyperkalemia in patients with chronic lymphocytic leukemia.
    Int J Hematol. 2021 Mar 29. pii: 10.1007/s12185-021-03142.
    PubMed     Abstract available
    
    
    
13. LEE H, Basso IN, Kim DDH
    Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.
    Int J Hematol. 2021 Mar 27. pii: 10.1007/s12185-021-03126.
    PubMed     Abstract available
    
    
    
14. NAKANO N, Takatsuka Y, Kubota A, Tokunaga M, et al
    Correction to: Cord blood transplantation with a reduced-intensity conditioning regimen using fludarabine and melphalan for adult T-cell leukemia/lymphoma.
    Int J Hematol. 2021 Mar 17. pii: 10.1007/s12185-021-03125.
    PubMed    
    
    
    
15. MORISHIGE S, Miyamoto T, Eto T, Uchida N, et al
    Clinical features and chromosomal/genetic aberration in adult acute lymphoblastic leukemia in Japan: results of Fukuoka Blood & Marrow Transplant Group Studies ALL MRD 2002 and 2008.
    Int J Hematol. 2021 Mar 16. pii: 10.1007/s12185-021-03116.
    PubMed     Abstract available
    
    
    
16. JUNG J, Lee E, Shim H, Park JH, et al
    Prediction of clinical outcomes through assessment of sarcopenia and adipopenia using computed tomography in adult patients with acute myeloid leukemia.
    Int J Hematol. 2021 Mar 10. pii: 10.1007/s12185-021-03122.
    PubMed     Abstract available
    
    
    
17. NAKA K
    New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism.
    Int J Hematol. 2021 Mar 5. pii: 10.1007/s12185-021-03112.
    PubMed     Abstract available
    
    
    
18. CHOI EJ, Lee JH, Kim H, Choi Y, et al
    Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial.
    Int J Hematol. 2021 Mar 2. pii: 10.1007/s12185-021-03099.
    PubMed     Abstract available
    
    
    
19. URESHINO H
    Treatment-free remission and immunity in chronic myeloid leukemia.
    Int J Hematol. 2021 Mar 2. pii: 10.1007/s12185-021-03117.
    PubMed     Abstract available
    
    
    February 2021
20. ISHIDA H, Yano M, Hasegawa D, Hori T, et al
    Prednisolone poor response is not an indication for HSCT in pediatric B-cell precursor acute lymphoblastic leukemia in first remission: results from JACLS ALL-02 study.
    Int J Hematol. 2021 Feb 28. pii: 10.1007/s12185-021-03110.
    PubMed     Abstract available
    
    
    
21. TERAKURA S, Kuwatsuka Y, Sugita J, Takahashi S, et al
    Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia.
    Int J Hematol. 2021 Feb 21. pii: 10.1007/s12185-021-03097.
    PubMed     Abstract available
    
    
    
22. NAKANO N, Takatsuka Y, Kubota A, Tokunaga M, et al
    Cord blood transplantation with a reduced-intensity conditioning regimen using fludarabine and melphalan for adult T-cell leukemia/lymphoma.
    Int J Hematol. 2021 Feb 16. pii: 10.1007/s12185-021-03102.
    PubMed     Abstract available
    
    
    
23. AKAHOSHI Y, Arai Y, Nishiwaki S, Mizuta S, et al
    Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Int J Hematol. 2021 Feb 11. pii: 10.1007/s12185-021-03094.
    PubMed     Abstract available
    
    
    
24. ONO R, Ashiarai M, Hirabayashi S, Mizuki K, et al
    Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
    Int J Hematol. 2021;113:297-301.
    PubMed     Abstract available
    
    
    January 2021
25. LIU Z, Li Y, Shi C
    Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy.
    Int J Hematol. 2021 Jan 27. pii: 10.1007/s12185-021-03085.
    PubMed     Abstract available
    
    
    
26. KUMAMOTO T, Goto H, Ogawa C, Hori T, et al
    Correction to: FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
    Int J Hematol. 2021 Jan 23. pii: 10.1007/s12185-020-03077.
    PubMed    
    
    
    
27. UENO T, Sugio Y, Ohta T, Uehara Y, et al
    Successful upfront cord blood transplantation for plasma cell leukemia in the first complete response after daratumumab therapy.
    Int J Hematol. 2021 Jan 22. pii: 10.1007/s12185-021-03082.
    PubMed     Abstract available
    
    
    
28. SAKAMOTO H, Itonaga H, Sawayama Y, Kojima A, et al
    Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma with HTLV-1-associated myelopathy.
    Int J Hematol. 2021 Jan 10. pii: 10.1007/s12185-020-03075.
    PubMed     Abstract available
    
    
    
29. NAKAMURA F, Arai H, Nannya Y, Ichikawa M, et al
    Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy.
    Int J Hematol. 2021 Jan 5. pii: 10.1007/s12185-020-03074.
    PubMed     Abstract available
    
    
    
30. FENG Y, Fu J
    Auer rods aid in the diagnosis of mixed phenotype acute leukemia.
    Int J Hematol. 2021 Jan 4. pii: 10.1007/s12185-020-03069.
    PubMed    
    
    
    
31. QUANN KA, Redner RL
    The eyes have it: CNS leukemia presenting as optic neuritis.
    Int J Hematol. 2021 Jan 4. pii: 10.1007/s12185-020-03065.
    PubMed    
    
    
    
32. NAKANO T, Kobayashi R, Matsushima S, Hori D, et al
    Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
    Int J Hematol. 2021 Jan 3. pii: 10.1007/s12185-020-03071.
    PubMed     Abstract available
    
    
    
33. LIU F, Xue S, Zhang Y, Yang J, et al
    Clostridium perfringens sepsis in three patients with acute leukemia and review of the literature.
    Int J Hematol. 2021 Jan 2. pii: 10.1007/s12185-020-03060.
    PubMed     Abstract available
    
    
    
34. XUE YJ, Wang Y, Jia YP, Zuo YX, et al
    The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia.
    Int J Hematol. 2021 Jan 1. pii: 10.1007/s12185-020-03063.
    PubMed     Abstract available
    
    
    
35. CAI Y, Liu C, Guo Y, Chen X, et al
    Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.
    Int J Hematol. 2021 Jan 1. pii: 10.1007/s12185-020-03042.
    PubMed     Abstract available
    
    
    
36. KINOSHITA H, Okamura D, Sato T, Taji Y, et al
    Cytokeratin expression in therapy-related leukemia.
    Int J Hematol. 2021 Jan 1. pii: 10.1007/s12185-020-03062.
    PubMed    
    
    
    
37. ITO F, Miura M, Fujioka Y, Abumiya M, et al
    The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration.
    Int J Hematol. 2021;113:100-105.
    PubMed     Abstract available
    
    
    November 2020
38. SAITO T, Hatta Y, Hayakawa F, Takahashi T, et al
    Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group.
    Int J Hematol. 2020 Nov 23. pii: 10.1007/s12185-020-03032.
    PubMed     Abstract available
    
    
    
39. HOSONO N, Ookura M, Araie H, Morita M, et al
    Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience.
    Int J Hematol. 2020 Nov 20. pii: 10.1007/s12185-020-03023.
    PubMed     Abstract available
    
    
    
40. INABA T, Tsukamoto T, Fujita N, Kuroda J, et al
    Auer-bodies in cellular components other than typical myeloblasts.
    Int J Hematol. 2020;112:605-606.
    PubMed    
    
    
    
41. KANAYAMA T, Imamura T, Mayumi A, Soma E, et al
    Functional analysis of a novel fusion protein PAX5-KIDINS220 identified in a pediatric Ph-like ALL patient.
    Int J Hematol. 2020;112:714-719.
    PubMed     Abstract available
    
    
    October 2020
42. IZUTSU K, Yamamoto K, Kato K, Ishikawa T, et al
    Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Int J Hematol. 2020 Oct 23. pii: 10.1007/s12185-020-03024.
    PubMed     Abstract available
    
    
    
43. ZHANG XW, Shen X, Long WY, Xiao H, et al
    Salt-inducible kinase inhibition sensitizes human acute myeloid leukemia cells to all-trans retinoic acid-induced differentiation.
    Int J Hematol. 2020 Oct 19. pii: 10.1007/s12185-020-03026.
    PubMed     Abstract available
    
    
    
44. NAKATANI K, Matsuo H, Harata Y, Higashitani M, et al
    Inhibition of CDK4/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells.
    Int J Hematol. 2020 Oct 17. pii: 10.1007/s12185-020-03015.
    PubMed     Abstract available
    
    
    
45. AMITAI I, Abulafia AS, Raanani P, Lipton JH, et al
    Chronic myeloid leukemia in solid organ transplant patients: a case series.
    Int J Hematol. 2020 Oct 6. pii: 10.1007/s12185-020-03014.
    PubMed     Abstract available
    
    
    
46. UCHIDA N, Matsumoto K, Sakura T, Hidaka M, et al
    Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies.
    Int J Hematol. 2020;112:510-523.
    PubMed     Abstract available
    
    
    September 2020
47. LIU B, Li T
    Relapsed acute monocytic leukemia presenting as histiocytic morphology.
    Int J Hematol. 2020 Sep 20. pii: 10.1007/s12185-020-02995.
    PubMed    
    
    
    
48. CORTES J, Podoltsev N, Kantarjian H, Borthakur G, et al
    Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
    Int J Hematol. 2020 Sep 20. pii: 10.1007/s12185-020-02994.
    PubMed     Abstract available
    
    
    
49. OYA S, Morishige S, Ozawa H, Sasaki K, et al
    Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
    Int J Hematol. 2020 Sep 19. pii: 10.1007/s12185-020-03006.
    PubMed     Abstract available
    
    
    
50. YABE M, Morio T, Tabuchi K, Tomizawa D, et al
    Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis.
    Int J Hematol. 2020 Sep 19. pii: 10.1007/s12185-020-02991.
    PubMed     Abstract available
    
    
    
51. MOROZOVA EA, Olisova OY, Nikitin EA
    Cutaneous manifestations of B-cell chronic lymphocytic leukemia.
    Int J Hematol. 2020 Sep 5. pii: 10.1007/s12185-020-02978.
    PubMed     Abstract available
    
    
    
52. OKAMOTO S, Ureshino H, Kimura S
    J-SKI will be able to elucidate whether the renal function recover or not after discontinuation of tyrosine kinase inhibitors.
    Int J Hematol. 2020;112:429-430.
    PubMed    
    
    
    August 2020
53. KIYOKI Y, Matsuoka R, Kaneta T, Nishikii H, et al
    (18)FDG-PET imaging and histopathology in neuroleukemiosis with acute myeloid leukemia.
    Int J Hematol. 2020 Aug 31. pii: 10.1007/s12185-020-02976.
    PubMed    
    
    
    
54. KIHIRA K, Chelakkot VS, Kainuma H, Okumura Y, et al
    Close interaction with bone marrow mesenchymal stromal cells induces the development of cancer stem cell-like immunophenotype in B cell precursor acute lymphoblastic leukemia cells.
    Int J Hematol. 2020 Aug 30. pii: 10.1007/s12185-020-02981.
    PubMed     Abstract available
    
    
    
55. HATTA Y, Hayakawa F, Yamazaki E
    JSH practical guidelines for hematological malignancies, 2018: I. leukemia-3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL).
    Int J Hematol. 2020 Aug 18. pii: 10.1007/s12185-020-02965.
    PubMed    
    
    
    
56. SHIMODA K, Takahashi N, Kirito K, Iriyama N, et al
    JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).
    Int J Hematol. 2020 Aug 11. pii: 10.1007/s12185-020-02964.
    PubMed    
    
    
    
57. KUMAMOTO T, Goto H, Ogawa C, Hori T, et al
    FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
    Int J Hematol. 2020 Aug 6. pii: 10.1007/s12185-020-02962.
    PubMed     Abstract available
    
    
    
58. KUROSAWA S, Yamaguchi H, Yamaguchi T, Fukunaga K, et al
    The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse.
    Int J Hematol. 2020;112:200-209.
    PubMed     Abstract available
    
    
    
59. ANDO T, Sano H, Yokoo M, Kusaba K, et al
    Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.
    Int J Hematol. 2020;112:249-253.
    PubMed     Abstract available
    
    
    July 2020
60. SAITO M, Hasegawa H, Yamauchi S, Nakagawa S, et al
    A high-throughput detection method for the clonality of Human T-cell leukemia virus type-1-infected cells in vivo.
    Int J Hematol. 2020 Jul 29. pii: 10.1007/s12185-020-02935.
    PubMed     Abstract available
    
    
    
61. LI YW, Xu YF, Hu W, Qian SX, et al
    Acute myeloid leukemia during pregnancy: a single institutional experience with 17 patients and literature review.
    Int J Hematol. 2020 Jul 18. pii: 10.1007/s12185-020-02938.
    PubMed     Abstract available
    
    
    
62. HUANG Y, Zhang L
    Intracellular rod-like crystals in chronic lymphocyte leukemia.
    Int J Hematol. 2020 Jul 14. pii: 10.1007/s12185-020-02933.
    PubMed    
    
    
    
63. CHILMI S, Nakahata S, Fauzi YR, Ichikawa T, et al
    Development of anti-human CADM1 monoclonal antibodies as a potential therapy for adult T-cell leukemia/lymphoma.
    Int J Hematol. 2020 Jul 12. pii: 10.1007/s12185-020-02939.
    PubMed     Abstract available
    
    
    
64. HENZAN H, Takase K, Kamimura T, Mori Y, et al
    Correction to: Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Int J Hematol. 2020 Jul 8. pii: 10.1007/s12185-020-02932.
    PubMed     Abstract available
    
    
    
65. ANDO T, Fujisawa S, Teshigawara H, Matsumura A, et al
    Computed tomography-defined sarcopenia: prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
    Int J Hematol. 2020;112:46-56.
    PubMed     Abstract available
    
    
    
66. MARKLIN M, Hagelstein I, Hinterleitner C, Salih HR, et al
    CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation.
    Int J Hematol. 2020;112:57-64.
    PubMed     Abstract available
    
    
    June 2020
67. HORIBE K, Morris JD, Tuglus CA, Dos Santos C, et al
    A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Int J Hematol. 2020 Jun 20. pii: 10.1007/s12185-020-02907.
    PubMed     Abstract available
    
    
    
68. SEKI Y, Nagano O, Koda R, Morita S, et al
    Pathological findings suggesting vascular endothelial damage in multiple organs in chronic myelogenous leukemia patients on long-term tyrosine kinase inhibitor therapy.
    Int J Hematol. 2020 Jun 18. pii: 10.1007/s12185-020-02913.
    PubMed     Abstract available
    
    
    
69. KIMURA SI, Fujita H, Handa H, Hiramoto N, et al
    Real-world management of infection during chemotherapy for acute leukemia in Japan: from the results of a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group.
    Int J Hematol. 2020 Jun 18. pii: 10.1007/s12185-020-02921.
    PubMed     Abstract available
    
    
    
70. URESHINO H, Kamachi K
    Vascular events may predict the prognosis of patients with chronic myeloid leukemia.
    Int J Hematol. 2020 Jun 12. pii: 10.1007/s12185-020-02889.
    PubMed    
    
    
    
71. HENZAN H, Takase K, Kamimura T, Mori Y, et al
    Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Int J Hematol. 2020 Jun 10. pii: 10.1007/s12185-020-02911.
    PubMed     Abstract available
    
    
    
72. LUCIJANIC M, Krecak I
    Effect of age and comorbidities on the decline of glomerular filtration rate in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors.
    Int J Hematol. 2020 Jun 9. pii: 10.1007/s12185-020-02915.
    PubMed    
    
    
    
73. KANAYA M, Kondo T
    Diffuse alveolar hemorrhage during induction therapy for acute myeloid leukemia with inv(16)(p13.1q22).
    Int J Hematol. 2020 Jun 6. pii: 10.1007/s12185-020-02900.
    PubMed    
    
    
    
74. ZHOU X, Zheng M, Wang Q, Aa J, et al
    Metabolomics analysis identifies lysine and taurine as candidate prognostic biomarkers for AML-M2 patients.
    Int J Hematol. 2020;111:761-770.
    PubMed     Abstract available
    
    
    
75. TAKEDA R, Ishigaki T, Ohno N, Yokoyama K, et al
    Immunophenotypic analysis of cerebrospinal fluid reveals concurrent development of ATL in the CNS of a HAM/TSP patient.
    Int J Hematol. 2020;111:891-896.
    PubMed     Abstract available
    
    
    May 2020
76. YOSHINO H, Nishiyama Y, Kamma H, Chiba T, et al
    Functional characterization of a germline ETV6 variant associated with inherited thrombocytopenia, acute lymphoblastic leukemia, and salivary gland carcinoma in childhood.
    Int J Hematol. 2020 May 4. pii: 10.1007/s12185-020-02885.
    PubMed     Abstract available
    
    
    
77. SAWAKI A, Miyazaki K, Yamaguchi M, Takeuchi T, et al
    Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy.
    Int J Hematol. 2020;111:686-691.
    PubMed     Abstract available
    
    
    
78. URESHINO H, Shindo T, Sano H, Kubota Y, et al
    Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2020;111:733-738.
    PubMed     Abstract available
    
    
    
79. KAGEYAMA Y, Katayama N
    Ontogeny of human B1 cells.
    Int J Hematol. 2020;111:628-633.
    PubMed     Abstract available
    
    
    April 2020
80. FUJITA H, Ishikawa Y, Yokoyama Y
    JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-2. Acute promyelocytic leukemia (APL).
    Int J Hematol. 2020 Apr 28. pii: 10.1007/s12185-020-02884.
    PubMed    
    
    
    
81. OKAMOTO S, Ureshino H, Kawaguchi A, Miyazono M, et al
    Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors.
    Int J Hematol. 2020 Apr 18. pii: 10.1007/s12185-020-02880.
    PubMed     Abstract available
    
    
    
82. HINO M, Matsumura I, Fujisawa S, Ishizawa K, et al
    Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Int J Hematol. 2020 Apr 11. pii: 10.1007/s12185-020-02878.
    PubMed     Abstract available
    
    
    
83. SUZUMIYA J, Takizawa J
    Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
    Int J Hematol. 2020 Apr 6. pii: 10.1007/s12185-020-02867.
    PubMed     Abstract available
    
    
    
84. SABURI M, Ogata M, Satou T, Soga Y, et al
    Prognostic implications of TdT expression in acute myeloid leukemia with an intermediate-risk karyotype.
    Int J Hematol. 2020 Apr 6. pii: 10.1007/s12185-020-02871.
    PubMed     Abstract available
    
    
    March 2020
85. YAMAGUCHI H, Inokuchi K
    No sex-related difference in achievement of treatment-free remission following treatment with tyrosine kinase inhibitors in chronic myeloid leukemia.
    Int J Hematol. 2020 Mar 31. pii: 10.1007/s12185-020-02865.
    PubMed    
    
    
    
86. KIYOI H, Yamaguchi H, Maeda Y, Yamauchi T, et al
    JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-1. Acute myeloid leukemia (AML).
    Int J Hematol. 2020 Mar 23. pii: 10.1007/s12185-020-02856.
    PubMed    
    
    
    
87. URESHINO H, Kamachi K, Kimura S
    Does patient sex play a role in treatment-free remission in chronic myeloid leukemia?
    Int J Hematol. 2020 Mar 21. pii: 10.1007/s12185-020-02864.
    PubMed    
    
    
    
88. KIDA M, Kuroda Y, Kido M, Chishaki R, et al
    Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.
    Int J Hematol. 2020 Mar 13. pii: 10.1007/s12185-020-02855.
    PubMed     Abstract available
    
    
    
89. MORI J, Oshima K, Tanimoto T, Ishizuka H, et al
    Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease.
    Int J Hematol. 2020 Mar 9. pii: 10.1007/s12185-020-02846.
    PubMed     Abstract available
    
    
    
90. KOUTAKE Y, Taniguchi J, Yasumori N, Nagaishi H, et al
    Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients.
    Int J Hematol. 2020 Mar 9. pii: 10.1007/s12185-020-02845.
    PubMed     Abstract available
    
    
    
91. SAKURAI M, Okamoto S, Matsumura I, Murakami S, et al
    Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line.
    Int J Hematol. 2020 Mar 9. pii: 10.1007/s12185-020-02843.
    PubMed     Abstract available
    
    
    
92. NAKAMURA D, Yoshimitsu M, Tabuchi T, Arima N, et al
    Correction to: Treatment of aggressive adult T-cell leukemia/lymphoma: a retrospective study in a hospital located in HTLV-1 highly endemic area.
    Int J Hematol. 2020 Mar 6. pii: 10.1007/s12185-020-02850.
    PubMed     Abstract available
    
    
    February 2020
93. MIYAZAKI Y
    JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-6 myelodysplastic syndromes (MDS).
    Int J Hematol. 2020 Feb 14. pii: 10.1007/s12185-020-02838.
    PubMed    
    
    
    
94. OKURA E, Saito S, Natsume T, Morita D, et al
    Multiple heterogeneous bone invasions of B lymphoblastic lymphoma with the TCF3/PBX1 fusion gene: a case report.
    Int J Hematol. 2020;111:163-165.
    PubMed    
    
    
    
95. POLPRASERT C, Takeda J, Niparuck P, Rattanathammethee T, et al
    Novel DDX41 variants in Thai patients with myeloid neoplasms.
    Int J Hematol. 2020;111:241-246.
    PubMed     Abstract available
    
    
    
96. UEDA T, Jo T, Okada K, Arai Y, et al
    Curative potential of fludarabine, melphalan, and non-myeloablative dosage of busulfan in elderly patients with myeloid malignancy.
    Int J Hematol. 2020;111:247-255.
    PubMed     Abstract available
    
    
    January 2020
97. YAMAGUCHI H, Takezako N, Ohashi K, Oba K, et al
    Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group.
    Int J Hematol. 2020 Jan 1. pii: 10.1007/s12185-019-02801.
    PubMed     Abstract available
    
    
    
98. HAGIHARA M, Hua J, Inoue M, Uchida T, et al
    Nilotinib treatment induced large granular lymphocyte expansion and maintenance of longitudinal remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Int J Hematol. 2020 Jan 1. pii: 10.1007/s12185-019-02789.
    PubMed     Abstract available
    
    
    December 2019
99. THANH NHA UYEN L, Amano Y, Al-Kzayer LFY, Kubota N, et al
    PCDH17 functions as a common tumor suppressor gene in acute leukemia and its transcriptional downregulation is mediated primarily by aberrant histone acetylation, not DNA methylation.
    Int J Hematol. 2019 Dec 21. pii: 10.1007/s12185-019-02799.
    PubMed     Abstract available
    
    
    
100. SHIN H, Choi SY, Kee KM, Kim SH, et al
     Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia.
     Int J Hematol. 2019 Dec 20. pii: 10.1007/s12185-019-02805.
     PubMed     Abstract available
     
     
     
101. HARADA-SHIRADO K, Wang X, Mori H, Fukatsu M, et al
     Circulating intranuclear proteins may play a role in development of disseminated intravascular coagulation in individuals with acute leukemia.
     Int J Hematol. 2019 Dec 17. pii: 10.1007/s12185-019-02798.
     PubMed     Abstract available
     
     
     
102. KIKUSHIGE Y
     Pathophysiology of chronic lymphocytic leukemia and human B1 cell development.
     Int J Hematol. 2019 Dec 3. pii: 10.1007/s12185-019-02788.
     PubMed     Abstract available
     
     
     November 2019
103. DUPLOYEZ N, Bories C
     Mature neutrophils with Auer rod bundles in CBFB-MYH11-positive acute myeloid leukemia.
     Int J Hematol. 2019 Nov 12. pii: 10.1007/s12185-019-02781.
     PubMed    
     
     
     
104. NAKAMURA D, Yoshimitsu M, Tabuchi T, Arima N, et al
     Treatment of aggressive adult T-cell leukemia/lymphoma: a retrospective study in a hospital located in HTLV-1 highly endemic area.
     Int J Hematol. 2019 Nov 12. pii: 10.1007/s12185-019-02769.
     PubMed     Abstract available
     
     
     
105. HIRAMATSU H, Adachi S, Umeda K, Kato I, et al
     Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia.
     Int J Hematol. 2019 Nov 11. pii: 10.1007/s12185-019-02771.
     PubMed     Abstract available
     
     
     
106. FUJI S, Kurosawa S, Inamoto Y, Murata T, et al
     A decision analysis comparing unrelated bone marrow transplantation and cord blood transplantation in patients with aggressive adult T-cell leukemia-lymphoma.
     Int J Hematol. 2019 Nov 7. pii: 10.1007/s12185-019-02777.
     PubMed     Abstract available
     
     
     
107. KAWABATA H, Usuki K, Shindo-Ueda M, Kanda J, et al
     Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes.
     Int J Hematol. 2019;110:533-542.
     PubMed     Abstract available
     
     
     October 2019
108. FUJISHIMA N, Uchida T, Onishi Y, Jung CW, et al
     Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.
     Int J Hematol. 2019 Oct 26. pii: 10.1007/s12185-019-02749.
     PubMed     Abstract available
     
     
     
109. DESCHNER M, Phua C, Saini L, Xenocostas A, et al
     Muscle aches and pains: do I have leukemia?
     Int J Hematol. 2019 Oct 14. pii: 10.1007/s12185-019-02746.
     PubMed     Abstract available
     
     
     
110. YANADA M, Takami A, Mizuno S, Mori J, et al
     Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan.
     Int J Hematol. 2019 Oct 14. pii: 10.1007/s12185-019-02759.
     PubMed     Abstract available
     
     
     
111. KONDO T, Fujioka M, Fujisawa S, Sato K, et al
     Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test.
     Int J Hematol. 2019;110:482-489.
     PubMed     Abstract available
     
     
     September 2019
112. KIM J, Park J, Moon Y, Choi SJ, et al
     Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: a systematic review and meta-analysis.
     Int J Hematol. 2019 Sep 27. pii: 10.1007/s12185-019-02744.
     PubMed     Abstract available
     
     
     
113. OSONE S, Fukushima K, Yano M, Kakazu M, et al
     Supportive care for hemostatic complications associated with pediatric leukemia: a national survey in Japan.
     Int J Hematol. 2019 Sep 26. pii: 10.1007/s12185-019-02740.
     PubMed     Abstract available
     
     
     
114. MA Y, Leng Q, Zhao Y, Wang E, et al
     Promyelocyte-like blasts in B-lymphoblastic leukemia of a 67-year-old male patient.
     Int J Hematol. 2019 Sep 25. pii: 10.1007/s12185-019-02732.
     PubMed    
     
     
     
115. NAGAFUJI K, Matsumura I, Shimose T, Kawaguchi T, et al
     Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).
     Int J Hematol. 2019 Sep 19. pii: 10.1007/s12185-019-02736.
     PubMed     Abstract available
     
     
     
116. FUJIOKA M, Itonaga H, Kato T, Nannya Y, et al
     Persistent clonal cytogenetic abnormality with del(20q) from an initial diagnosis of acute promyelocytic leukemia.
     Int J Hematol. 2019 Sep 12. pii: 10.1007/s12185-019-02731.
     PubMed     Abstract available
     
     
     
117. WRIGHT N, Voshtina E, George G, Singavi A, et al
     Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL).
     Int J Hematol. 2019 Sep 7. pii: 10.1007/s12185-019-02729.
     PubMed     Abstract available
     
     
     
118. OHTA T, Sugio Y, Imanaga H, Oku S, et al
     Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS.
     Int J Hematol. 2019;110:347-354.
     PubMed     Abstract available
     
     
     August 2019
119. TAKAHASHI T, Usuki K, Matsue K, Ohno H, et al
     Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study.
     Int J Hematol. 2019 Aug 31. pii: 10.1007/s12185-019-02727.
     PubMed     Abstract available
     
     
     
120. SAKAMOTO Y, Fujii K, Murase S, Nakano S, et al
     CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma.
     Int J Hematol. 2019 Aug 29. pii: 10.1007/s12185-019-02728.
     PubMed     Abstract available
     
     
     
121. ZHOU F, Zhou F, Du M, Liu L, et al
     Comprehensive prognostic scoring systems could improve the prognosis of adult acute myeloid leukemia patients.
     Int J Hematol. 2019 Aug 22. pii: 10.1007/s12185-019-02721.
     PubMed     Abstract available
     
     
     
122. SAKAGUCHI M, Yamaguchi H, Kuboyama M, Najima Y, et al
     Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia.
     Int J Hematol. 2019 Aug 20. pii: 10.1007/s12185-019-02720.
     PubMed     Abstract available
     
     
     
123. MORIYAMA K, Hori T
     BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of Survivin and Cyclin D1 in chronic myeloid leukemia cells.
     Int J Hematol. 2019 Aug 19. pii: 10.1007/s12185-019-02726.
     PubMed     Abstract available
     
     
     
124. HASEGAWA D, Yoshimoto Y, Kimura S, Kumamoto T, et al
     Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia.
     Int J Hematol. 2019 Aug 10. pii: 10.1007/s12185-019-02714.
     PubMed     Abstract available
     
     
     
125. SAKAKIBARA K, Tsujioka T, Kida JI, Kurozumi N, et al
     Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
     Int J Hematol. 2019;110:213-227.
     PubMed     Abstract available
     
     
     
126. DUCHMANN M, Itzykson R
     Clinical update on hypomethylating agents.
     Int J Hematol. 2019;110:161-169.
     PubMed     Abstract available
     
     
     
127. ASADA S, Kitamura T
     Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
     Int J Hematol. 2019;110:179-186.
     PubMed     Abstract available
     
     
     July 2019
128. USUKI K, Handa H, Choi I, Yamauchi T, et al
     Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study.
     Int J Hematol. 2019 Jul 29. pii: 10.1007/s12185-019-02709.
     PubMed     Abstract available
     
     
     
129. LI C, Cai X, Chen X, Liang Y, et al
     Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study.
     Int J Hematol. 2019 Jul 18. pii: 10.1007/s12185-019-02703.
     PubMed     Abstract available
     
     
     
130. MIZUTANI Y, Inase A, Maimaitili Y, Miyata Y, et al
     An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells.
     Int J Hematol. 2019 Jul 8. pii: 10.1007/s12185-019-02701.
     PubMed     Abstract available
     
     
     
131. COHEN CT, Bergstrom KL, Xiao R, Elghetany MT, et al
     First case of neutropenia and thrombocytopenia in the setting of cerebral cavernous malformation 3.
     Int J Hematol. 2019;110:95-101.
     PubMed     Abstract available
     
     
     June 2019
132. ALFANO G, Fontana F, Colaci E, Mori G, et al
     T-cell large granular lymphocyte leukemia in solid organ transplant recipients: case series and review of the literature.
     Int J Hematol. 2019 Jun 27. pii: 10.1007/s12185-019-02682.
     PubMed     Abstract available
     
     
     
133. TAKACHI T, Arakawa Y, Nakamura H, Watanabe T, et al
     Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia.
     Int J Hematol. 2019 Jun 14. pii: 10.1007/s12185-019-02684.
     PubMed     Abstract available
     
     
     
134. TANTIWORAWIT A, Rattanathammethee T, Chai-Adisaksopha C, Rattarittamrong E, et al
     Outcomes of adult acute lymphoblastic leukemia in the era of pediatric-inspired regimens: a single-center experience.
     Int J Hematol. 2019 Jun 3. pii: 10.1007/s12185-019-02678.
     PubMed     Abstract available
     
     
     May 2019
135. MORISHIGE S, Nishi M, Saruta H, Arakawa F, et al
     Complete response following toxic epidermal necrolysis in relapsed adult T cell leukemia/lymphoma after haploidentical stem cell transplantation.
     Int J Hematol. 2019 May 31. pii: 10.1007/s12185-019-02675.
     PubMed     Abstract available
     
     
     
136. MITANI Y, Hiwatari M, Seki M, Hangai M, et al
     Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusions.
     Int J Hematol. 2019 May 27. pii: 10.1007/s12185-019-02665.
     PubMed     Abstract available
     
     
     
137. TYAGI A, Pramanik R, Bakhshi R, Singh A, et al
     Expression of mitochondrial genes predicts survival in pediatric acute myeloid leukemia.
     Int J Hematol. 2019 May 22. pii: 10.1007/s12185-019-02666.
     PubMed     Abstract available
     
     
     
138. YANG JL, Liu YN, Bi YY, Wang H, et al
     ARID5B gene polymorphisms and the risk of childhood acute lymphoblastic leukemia: a meta-analysis.
     Int J Hematol. 2019 May 20. pii: 10.1007/s12185-019-02658.
     PubMed     Abstract available
     
     
     
139. NISHIO Y, Sakai H, Saiki Y, Uchida A, et al
     Light-chain plasma cell myeloma caused by 14q32/IGH translocation and loss of the other allele.
     Int J Hematol. 2019;109:572-577.
     PubMed     Abstract available
     
     
     April 2019
140. ANDO T, Fujisawa S, Teshigawara H, Ogusa E, et al
     Impact of treatment-related weight changes from diagnosis to hematopoietic stem-cell transplantation on clinical outcome of acute myeloid leukemia.
     Int J Hematol. 2019 Apr 8. pii: 10.1007/s12185-019-02647.
     PubMed     Abstract available
     
     
     March 2019
141. SASAKI H, Mitani S, Kusumoto S, Marumo Y, et al
     Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation.
     Int J Hematol. 2019 Mar 16. pii: 10.1007/s12185-019-02628.
     PubMed     Abstract available
     
     
     
142. FUJINO H, Ishida H, Iguchi A, Onuma M, et al
     High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia: an analysis from the Japan Association of Childhood Leukemia Study (JACLS).
     Int J Hematol. 2019 Mar 12. pii: 10.1007/s12185-019-02627.
     PubMed     Abstract available
     
     
     
143. ARAI N, Homma M, Abe M, Baba Y, et al
     Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia.
     Int J Hematol. 2019 Mar 7. pii: 10.1007/s12185-019-02616.
     PubMed     Abstract available
     
     
     
144. SASAKI K, Kantarjian HM, O'Brien S, Ravandi F, et al
     Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
     Int J Hematol. 2019 Mar 4. pii: 10.1007/s12185-019-02620.
     PubMed     Abstract available
     
     
     
145. TOBINAI K, Uchida T, Fukuhara N, Nishikawa T, et al
     Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
     Int J Hematol. 2019;109:366-368.
     PubMed    
     
     
     February 2019
146. ARAI K, Yoshifuji K, Motomura Y, Sonokawa S, et al
     Dasatinib for chronic myelogenous leukemia improves skin symptoms of systemic sclerosis.
     Int J Hematol. 2019 Feb 20. pii: 10.1007/s12185-019-02618.
     PubMed     Abstract available
     
     
     
147. KIZAKI M, Takahashi N, Iriyama N, Okamoto S, et al
     Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.
     Int J Hematol. 2019 Feb 14. pii: 10.1007/s12185-019-02613.
     PubMed     Abstract available
     
     
     
148. HATSUMI N, Miyawaki S, Yamauchi T, Takeshita A, et al
     Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.
     Int J Hematol. 2019 Feb 6. pii: 10.1007/s12185-019-02606.
     PubMed     Abstract available
     
     
     January 2019
149. YAMASHITA Y, Nishikawa A, Iwahashi Y, Fujimoto M, et al
     Identification of a novel CCDC22 mutation in a patient with severe Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and aggressive natural killer cell leukemia.
     Int J Hematol. 2019 Jan 31. pii: 10.1007/s12185-019-02595.
     PubMed     Abstract available
     
     
     
150. TSUKASAKI K, Fukushima T
     JSH Practical Guidelines for Hematological Malignancies, 2018: II. Lymphoma-8. Adult T-cell leukemia-lymphoma.
     Int J Hematol. 2019 Jan 30. pii: 10.1007/s12185-018-02588.
     PubMed    
     
     
     
151. USAMI I, Imamura T, Takahashi Y, Suenobu SI, et al
     Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
     Int J Hematol. 2019 Jan 28. pii: 10.1007/s12185-019-02599.
     PubMed     Abstract available
     
     
     
152. KAWASAKI Y, Kimura SI, Nakano H, Mashima K, et al
     Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.
     Int J Hematol. 2019 Jan 25. pii: 10.1007/s12185-019-02593.
     PubMed     Abstract available
     
     
     
153. SAKURAI M, Kikuchi T, Karigane D, Kasahara H, et al
     Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia.
     Int J Hematol. 2019 Jan 24. pii: 10.1007/s12185-019-02596.
     PubMed     Abstract available
     
     
     
154. TANIGUCHI H, Imaizumi Y, Takasaki Y, Nakashima J, et al
     Clinical features at transformation in adult T-cell leukemia-lymphoma with smoldering and chronic types.
     Int J Hematol. 2019 Jan 24. pii: 10.1007/s12185-019-02602.
     PubMed     Abstract available
     
     
     
155. TANAKA Y, Takahashi Y, Tanaka R, Miyagi T, et al
     Association of high levels of plasma OX40 with acute adult T-cell leukemia.
     Int J Hematol. 2019 Jan 16. pii: 10.1007/s12185-018-02580.
     PubMed     Abstract available
     
     
     
156. BRUNETTI L, Gundry MC, Goodell MA
     New insights into the biology of acute myeloid leukemia with mutated NPM1.
     Int J Hematol. 2019 Jan 10. pii: 10.1007/s12185-018-02578.
     PubMed     Abstract available
     
     
     December 2018
157. DOTSON J, Elhamdani A, Petryna E, Jamil MO, et al
     Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin.
     Int J Hematol. 2018 Dec 3. pii: 10.1007/s12185-018-2558.
     PubMed     Abstract available
     
     
     
158. TACHIBANA T, Koyama S, Andou T, Ishiyama Y, et al
     Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia.
     Int J Hematol. 2018 Dec 3. pii: 10.1007/s12185-018-02571.
     PubMed     Abstract available
     
     
     
159. STANO KOZUBIK K, Radova L, Pesova M, Reblova K, et al
     C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies.
     Int J Hematol. 2018;108:652-657.
     PubMed     Abstract available
     
     
     November 2018
160. UEDA T, Maeda T, Kusakabe S, Fujita J, et al
     Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.
     Int J Hematol. 2018 Nov 17. pii: 10.1007/s12185-018-2562.
     PubMed     Abstract available
     
     
     
161. WOLTERS R, Curry CV
     Conspicuous activated lymphocytic proliferation associated with cytokine-release syndrome after CAR T-cell therapy.
     Int J Hematol. 2018;108:461-462.
     PubMed    
     
     
     
162. DOTSON JL, Jamil MO
     Successful treatment of cytarabine-related neurotoxicity with corticosteroids, a case series.
     Int J Hematol. 2018;108:554-557.
     PubMed     Abstract available
     
     
     
163. KUAN JW, Su AT, Leong CF, Osato M, et al
     Systematic review of pre-clinical chronic myeloid leukaemia.
     Int J Hematol. 2018;108:465-484.
     PubMed     Abstract available
     
     
     
164. OYA S, Muta T
     Breakthrough infection of Geotrichum capitatum during empirical caspofungin therapy after umbilical cord blood transplantation.
     Int J Hematol. 2018;108:558-563.
     PubMed     Abstract available
     
     
     October 2018
165. KAMACHI K, Shindo T, Miyahara M, Kitaura K, et al
     Epstein-Barr virus-related diffuse large B-cell lymphoma in mogamulizumab-treated adult T-cell leukemia with incomplete T-cell reconstitution.
     Int J Hematol. 2018 Oct 27. pii: 10.1007/s12185-018-2552.
     PubMed     Abstract available
     
     
     
166. KIZAKI M
     Molecular pathogenesis of leukemia and leukemic stem cells (LSCs).
     Int J Hematol. 2018 Oct 23. pii: 10.1007/s12185-018-2550.
     PubMed    
     
     
     
167. HARADA K, Sekiya N, Ikegawa S, Sasaki S, et al
     Cytomegalovirus meningitis in a patient with relapsed acute myeloid leukemia.
     Int J Hematol. 2018 Oct 5. pii: 10.1007/s12185-018-2544.
     PubMed     Abstract available
     
     
     
168. TAGA T, Imamura T, Nakashima K, Maeda N, et al
     Clinical characteristics of pediatric patients with myeloid sarcoma without bone marrow involvement in Japan.
     Int J Hematol. 2018;108:438-442.
     PubMed     Abstract available
     
     
     September 2018
169. AZEVEDO PORTILHO N, Kobayashi M, Yoshimoto M
     What do the lineage tracing studies tell us? Consideration for hematopoietic stem cell origin, dynamics, and leukemia-initiating cells.
     Int J Hematol. 2018 Sep 27. pii: 10.1007/s12185-018-2537.
     PubMed     Abstract available
     
     
     
170. RAKSZAWSKI K, Miki K, Claxton D, Wagner H, et al
     Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML.
     Int J Hematol. 2018;108:348-350.
     PubMed     Abstract available
     
     
     August 2018
171. MINAMI Y
     Guest editorial: chronic myeloid leukemia.
     Int J Hematol. 2018 Aug 28. pii: 10.1007/s12185-018-2521.
     PubMed    
     
     
     
172. INOUE A, Kobayashi CI, Shinohara H, Miyamoto K, et al
     Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.
     Int J Hematol. 2018 Aug 28. pii: 10.1007/s12185-018-2519.
     PubMed     Abstract available
     
     
     
173. WATANABE N, Takaku T, Takeda K, Shirane S, et al
     Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients.
     Int J Hematol. 2018 Aug 27. pii: 10.1007/s12185-018-2517.
     PubMed     Abstract available
     
     
     
174. TAN TK, Zhang C, Sanda T
     Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia.
     Int J Hematol. 2018 Aug 25. pii: 10.1007/s12185-018-2518.
     PubMed     Abstract available
     
     
     
175. KANAYAMA T, Imamura T, Kawabe Y, Osone S, et al
     KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
     Int J Hematol. 2018 Aug 24. pii: 10.1007/s12185-018-2522.
     PubMed     Abstract available
     
     
     
176. SATO K, Sakai H, Saiki Y, Uchida A, et al
     Correction to: Cell dynamics during differentiation therapy with all-trans retinoic acid in acute promyelocytic leukemia.
     Int J Hematol. 2018 Aug 12. pii: 10.1007/s12185-018-2515.
     PubMed     Abstract available
     
     
     
177. CHIBA A, Toya T, Mizuno H, Tokushige J, et al
     Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation.
     Int J Hematol. 2018 Aug 4. pii: 10.1007/s12185-018-2511.
     PubMed     Abstract available
     
     
     
178. EVERS D, Bar BMAM, Gotthardt M, van der Velden WJFM, et al
     Activity of decitabine in pericardial myeloid sarcoma.
     Int J Hematol. 2018;108:121-122.
     PubMed    
     
     
     July 2018
179. ITAMURA H, Ide M, Sato A, Sueoka-Aragane N, et al
     Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method.
     Int J Hematol. 2018 Jul 24. pii: 10.1007/s12185-018-2506.
     PubMed     Abstract available
     
     
     
180. NAKASHIMA J, Imaizumi Y, Taniguchi H, Ando K, et al
     Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma.
     Int J Hematol. 2018 Jul 21. pii: 10.1007/s12185-018-2509.
     PubMed     Abstract available
     
     
     
181. KURATA K, Nishimura S, Ichikawa H, Sakai R, et al
     Invasive Scopulariopsis alboflavescens infection in patient with acute myeloid leukemia.
     Int J Hematol. 2018 Jul 9. pii: 10.1007/s12185-018-2496.
     PubMed     Abstract available
     
     
     June 2018
182. TAKEI H, Kobayashi SS
     Targeting transcription factors in acute myeloid leukemia.
     Int J Hematol. 2018 Jun 28. pii: 10.1007/s12185-018-2488.
     PubMed     Abstract available
     
     
     
183. HASSAN IB, Kristensen J, Al Qawasmeh K, Alam A, et al
     Re-induction chemotherapy using FLAG-mitoxantrone for adult patients with relapsed acute leukemia: a single-center experience from United Arab Emirates.
     Int J Hematol. 2018 Jun 27. pii: 10.1007/s12185-018-2478.
     PubMed     Abstract available
     
     
     
184. ORAVCOVA I, Mikuskova E, Leitnerova M, Gyarfas J, et al
     A unique clinical presentation of de novo acute promyelocytic leukemia as a myeloid sarcoma of the breast.
     Int J Hematol. 2018 Jun 21. pii: 10.1007/s12185-018-2479.
     PubMed     Abstract available
     
     
     
185. KAWAI H, Matsushita H, Aoyama Y, Matsui K, et al
     Correction to: Dysplastic features seen in a patient with acute myeloid leukemia harboring the KMT2A-TET1 fusion gene.
     Int J Hematol. 2018 Jun 12. pii: 10.1007/s12185-018-2476.
     PubMed     Abstract available
     
     
     
186. WILKINSON AC, Yamazaki S
     The hematopoietic stem cell diet.
     Int J Hematol. 2018;107:634-641.
     PubMed     Abstract available
     
     
     
187. HOSOI H, Mushino T, Nishikawa A, Hashimoto H, et al
     Severe graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with residual mogamulizumab concentration.
     Int J Hematol. 2018;107:717-719.
     PubMed    
     
     
     May 2018
188. SATO K, Sakai H, Saiki Y, Uchida A, et al
     Cell dynamics during differentiation therapy with all-trans retinoic acid in acute promyelocytic leukemia.
     Int J Hematol. 2018 May 29. pii: 10.1007/s12185-018-2472.
     PubMed     Abstract available
     
     
     
189. TOMOYASU C, Imamura T, Tomii T, Yano M, et al
     Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.
     Int J Hematol. 2018 May 21. pii: 10.1007/s12185-018-2474.
     PubMed     Abstract available
     
     
     
190. KAWAI H, Matsushita H, Aoyama Y, Matsui K, et al
     Dysplastic features seen in a patient with acute myeloid leukemia harboring the KTM2A-TET1 fusion gene.
     Int J Hematol. 2018 May 9. pii: 10.1007/s12185-018-2469.
     PubMed    
     
     
     
191. GOTOH N, Saitoh T, Takahashi N, Kasamatsu T, et al
     Association between OGG1 S326C CC genotype and elevated relapse risk in acute myeloid leukemia.
     Int J Hematol. 2018 May 8. pii: 10.1007/s12185-018-2464.
     PubMed     Abstract available
     
     
     
192. ISHIKAWA J, Matsumura I, Kawaguchi T, Kuroda J, et al
     Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).
     Int J Hematol. 2018;107:535-540.
     PubMed     Abstract available
     
     
     April 2018
193. NOGUCHI S, Nakaseko C, Nishiwaki K, Ogasawara H, et al
     Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.
     Int J Hematol. 2018 Apr 30. pii: 10.1007/s12185-018-2459.
     PubMed     Abstract available
     
     
     
194. TORIYAMA E, Imaizumi Y, Taniguchi H, Taguchi J, et al
     EPOCH regimen as salvage therapy for adult T-cell leukemia-lymphoma.
     Int J Hematol. 2018 Apr 12. pii: 10.1007/s12185-018-2455.
     PubMed     Abstract available
     
     
     March 2018
195. WATANABE J, Sato K, Osawa Y, Horiuchi T, et al
     CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.
     Int J Hematol. 2018 Mar 29. pii: 10.1007/s12185-018-2436.
     PubMed     Abstract available
     
     
     
196. TAKAHASHI H, Kajiwara R, Kato M, Hasegawa D, et al
     Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16.
     Int J Hematol. 2018 Mar 27. pii: 10.1007/s12185-018-2440.
     PubMed     Abstract available
     
     
     
197. IMAMURA T, Taga T, Takagi M, Kawasaki H, et al
     Nationwide survey of therapy-related leukemia in childhood in Japan.
     Int J Hematol. 2018 Mar 24. pii: 10.1007/s12185-018-2439.
     PubMed     Abstract available
     
     
     
198. SANO H, Kobayashi R, Suzuki D, Hori D, et al
     Impact of the D-index deduced from duration and intensity of neutropenia following chemotherapy on the risk of invasive fungal infection in pediatric acute myeloid leukemia.
     Int J Hematol. 2018 Mar 21. pii: 10.1007/s12185-018-2433.
     PubMed     Abstract available
     
     
     
199. SANO H, Mochizuki K, Kobayashi S, Ohara Y, et al
     T-cell-replete haploidentical stem cell transplantation using low-dose antithymocyte globulin in children with relapsed or refractory acute leukemia.
     Int J Hematol. 2018 Mar 5. pii: 10.1007/s12185-018-2423.
     PubMed     Abstract available
     
     
     
200. MIYOSHI H, Ohshima K
     Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan.
     Int J Hematol. 2018 Mar 3. pii: 10.1007/s12185-018-2430.
     PubMed     Abstract available
     
     
     
201. KAWAMOTO H, Masuda K, Nagano S, Maeda T, et al
     Cloning and expansion of antigen-specific T cells using iPS cell technology: development of "off-the-shelf" T cells for the use in allogeneic transfusion settings.
     Int J Hematol. 2018;107:271-277.
     PubMed     Abstract available
     
     
     February 2018
202. SUEMATSU M, Imamura T, Chiyonobu T, Osone S, et al
     Lumbosacral polyradiculopathy after intrathecal chemotherapy in pediatric acute lymphoblastic leukemia.
     Int J Hematol. 2018 Feb 22. pii: 10.1007/s12185-018-2427.
     PubMed    
     
     
     
203. NAQVI K, Cortes JE, Luthra R, O'Brien S, et al
     Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.
     Int J Hematol. 2018 Feb 20. pii: 10.1007/s12185-018-2422.
     PubMed     Abstract available
     
     
     
204. SATO S, Itonaga H, Taguchi M, Sawayama Y, et al
     Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm.
     Int J Hematol. 2018 Feb 7. pii: 10.1007/s12185-018-2419.
     PubMed     Abstract available
     
     
     
205. SCHROEDER T, Rautenberg C, Haas R, Germing U, et al
     Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.
     Int J Hematol. 2018;107:138-150.
     PubMed     Abstract available
     
     
     
206. KOIZUMI Y, Furuya D, Endo T, Asanuma K, et al
     Quantification of Wilms' tumor 1 mRNA by digital polymerase chain reaction.
     Int J Hematol. 2018;107:230-234.
     PubMed     Abstract available
     
     
     January 2018
207. TAKAMI A
     Hematopoietic stem cell transplantation for acute myeloid leukemia.
     Int J Hematol. 2018 Jan 27. pii: 10.1007/s12185-018-2412.
     PubMed     Abstract available
     
     
     
208. SHIMADA A, Iijima-Yamashita Y, Tawa A, Tomizawa D, et al
     Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
     Int J Hematol. 2018 Jan 12. pii: 10.1007/s12185-017-2395.
     PubMed     Abstract available
     
     
     December 2017
209. ABE A, Yamamoto Y, Katsumi A, Okamoto A, et al
     Rearrangement of VPS13B, a causative gene of Cohen syndrome, in a case of RUNX1-RUNX1T1 leukemia with t(8;12;21).
     Int J Hematol. 2017 Dec 20. pii: 10.1007/s12185-017-2387.
     PubMed     Abstract available
     
     
     
210. MIYAMOTO T, Nagafuji K, Fujisaki T, Uchida N, et al
     Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.
     Int J Hematol. 2017 Dec 14. pii: 10.1007/s12185-017-2389.
     PubMed     Abstract available
     
     
     
211. SUZUKI D, Kobayashi R, Sano H, Hori D, et al
     Sarcopenia after induction therapy in childhood acute lymphoblastic leukemia: its clinical significance.
     Int J Hematol. 2017 Dec 12. pii: 10.1007/s12185-017-2388.
     PubMed     Abstract available
     
     
     November 2017
212. FUJIMAKI K, Hattori Y, Nakajima H
     10-year complete remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation.
     Int J Hematol. 2017 Nov 29. pii: 10.1007/s12185-017-2382.
     PubMed     Abstract available
     
     
     
213. KIKUCHI J, Kuroda Y, Koyama D, Furukawa Y, et al
     Cell adhesion-induced phosphorylation and inactivation of EZH2 confer drug resistance to acute myeloid leukemia cells.
     Int J Hematol. 2017 Nov 28. pii: 10.1007/s12185-017-2376.
     PubMed    
     
     
     
214. FUJIWARA SI, Shirato Y, Ikeda T, Kawaguchi SI, et al
     Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
     Int J Hematol. 2017 Nov 28. pii: 10.1007/s12185-017-2378.
     PubMed     Abstract available
     
     
     
215. YAMAMOTO M, Hori T, Igarashi K, Iesato K, et al
     Non-alcoholic steatohepatitis induced by induction chemotherapy for pediatric acute lymphoblastic leukemia.
     Int J Hematol. 2017 Nov 27. pii: 10.1007/s12185-017-2377.
     PubMed    
     
     
     
216. UEMURA S, Nishimura N, Hasegawa D, Shono A, et al
     ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.
     Int J Hematol. 2017 Nov 24. pii: 10.1007/s12185-017-2371.
     PubMed     Abstract available
     
     
     October 2017
217. COOK LB, Rowan AG, Demontis MA, Sagawe S, et al
     Long-term clinical remission maintained after cessation of zidovudine and interferon-alpha therapy in chronic adult T-cell leukemia/lymphoma.
     Int J Hematol. 2017 Oct 31. doi: 10.1007/s12185-017-2361.
     PubMed     Abstract available
     
     
     
218. NAKAMAE H, Fukuda T, Nakaseko C, Kanda Y, et al
     Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.
     Int J Hematol. 2017 Oct 26. doi: 10.1007/s12185-017-2353.
     PubMed     Abstract available
     
     
     
219. TAKEUCHI J, Kusumoto S, Akiyama H, Kanda Y, et al
     JSH guideline for tumors of hematopoietic and lymphoid tissues-leukemia: 3. Acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL).
     Int J Hematol. 2017 Oct 24. doi: 10.1007/s12185-017-2350.
     PubMed    
     
     
     
220. HONG CR, Kang HJ, Park KD, Shin HY, et al
     High-dose chemotherapy and autologous peripheral blood stem cell transplantation with BCVAC regimen followed by maintenance chemotherapy for children with very high risk acute lymphoblastic leukemia.
     Int J Hematol. 2017 Oct 20. doi: 10.1007/s12185-017-2355.
     PubMed     Abstract available
     
     
     
221. KOZAKAI T, Takahashi M, Higuchi M, Hara T, et al
     MAGI-1 expression is decreased in several types of human T-cell leukemia cell lines, including adult T-cell leukemia.
     Int J Hematol. 2017 Oct 17. doi: 10.1007/s12185-017-2359.
     PubMed     Abstract available
     
     
     
222. KOBAYASHI N, Shimizu H, Hirato J, Handa H, et al
     Collision of metastatic malignant melanoma and acute myelogenous leukemia in the bone marrow.
     Int J Hematol. 2017 Oct 17. doi: 10.1007/s12185-017-2356.
     PubMed    
     
     
     
223. OKADA Y, Sato K, Kobayashi S, Nagao S, et al
     Sudden blast phase in chronic myeloid leukemia developed during nilotinib therapy after major molecular response was achieved.
     Int J Hematol. 2017 Oct 14. doi: 10.1007/s12185-017-2354.
     PubMed     Abstract available
     
     
     
224. ISHIDA T, Akagawa N, Miyata T, Tominaga N, et al
     Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia.
     Int J Hematol. 2017 Oct 13. doi: 10.1007/s12185-017-2339.
     PubMed     Abstract available
     
     
     
225. WANG Y, Xing Y, Chen L, Meng T, et al
     Fluconazole versus mould-active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost-effectiveness analysis.
     Int J Hematol. 2017 Oct 13. doi: 10.1007/s12185-017-2342.
     PubMed     Abstract available
     
     
     
226. USUI N
     Correction to: JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
     Int J Hematol. 2017 Oct 12. doi: 10.1007/s12185-017-2351.
     PubMed     Abstract available
     
     
     
227. KUWATSUKA Y, Tomizawa D, Kihara R, Nagata Y, et al
     Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.
     Int J Hematol. 2017 Oct 12. doi: 10.1007/s12185-017-2340.
     PubMed     Abstract available
     
     
     September 2017
228. USUI N
     JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
     Int J Hematol. 2017 Sep 21. doi: 10.1007/s12185-017-2330.
     PubMed    
     
     
     
229. TAKAHASHI N, Tauchi T, Kitamura K, Miyamura K, et al
     Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.
     Int J Hematol. 2017 Sep 19. doi: 10.1007/s12185-017-2334.
     PubMed     Abstract available
     
     
     
230. KOBAYASHI Y, Munakata W, Ogura M, Uchida T, et al
     Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
     Int J Hematol. 2017 Sep 13. doi: 10.1007/s12185-017-2327.
     PubMed     Abstract available
     
     
     
231. DELIA D, Mizutani S
     The DNA damage response pathway in normal hematopoiesis and malignancies.
     Int J Hematol. 2017;106:328-334.
     PubMed     Abstract available
     
     
     August 2017
232. ASOU N, Fujita H, Shinagawa K
     JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia: 2. Acute promyelocytic leukemia (APL).
     Int J Hematol. 2017 Aug 30. doi: 10.1007/s12185-017-2318.
     PubMed    
     
     
     
233. KOTAKI R, Higuchi H, Ogiya D, Katahira Y, et al
     Imbalanced expression of polycistronic miRNA in acute myeloid leukemia.
     Int J Hematol. 2017 Aug 22. doi: 10.1007/s12185-017-2314.
     PubMed     Abstract available
     
     
     
234. HAN DM, Zheng XL, Ding L, Yan HM, et al
     Risk factors in patients undergoing haploidentical hematopoietic stem cell transplantation for high-risk childhood acute leukemia.
     Int J Hematol. 2017 Aug 20. doi: 10.1007/s12185-017-2317.
     PubMed     Abstract available
     
     
     
235. HARA R, Onizuka M, Matsusita E, Kikkawa E, et al
     NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib.
     Int J Hematol. 2017 Aug 9. doi: 10.1007/s12185-017-2294.
     PubMed     Abstract available
     
     
     
236. MIYAWAKI S
     JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML).
     Int J Hematol. 2017 Aug 7. doi: 10.1007/s12185-017-2303.
     PubMed    
     
     
     
237. FEURSTEIN S, Godley LA
     Germline ETV6 mutations and predisposition to hematological malignancies.
     Int J Hematol. 2017;106:189-195.
     PubMed     Abstract available
     
     
     
238. CHEAH JJC, Hahn CN, Hiwase DK, Scott HS, et al
     Myeloid neoplasms with germline DDX41 mutation.
     Int J Hematol. 2017;106:163-174.
     PubMed     Abstract available
     
     
     
239. HAYASHI Y, Harada Y, Huang G, Harada H, et al
     Myeloid neoplasms with germ line RUNX1 mutation.
     Int J Hematol. 2017;106:183-188.
     PubMed     Abstract available
     
     
     
240. HUA Y, Wang C, Jiang H, Wang Y, et al
     Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes.
     Int J Hematol. 2017;106:248-257.
     PubMed     Abstract available
     
     
     July 2017
241. GEYER JT, Mathew S
     Myelomonocytic leukemia with intracytoplasmic crystalline inclusions, double minute chromosomes and MYC amplification.
     Int J Hematol. 2017 Jul 28. doi: 10.1007/s12185-017-2299.
     PubMed    
     
     
     
242. DI IANNI M, Olioso P, Giancola R, Santarone S, et al
     Treg-protected donor lymphocyte infusions: a new tool to address the graft-versus-leukemia effect in the absence of graft-versus-host disease in patients relapsed after HSCT.
     Int J Hematol. 2017 Jul 18. doi: 10.1007/s12185-017-2292.
     PubMed     Abstract available
     
     
     
243. REA D, Cayuela JM
     Treatment-free remission in patients with chronic myeloid leukemia.
     Int J Hematol. 2017 Jul 8. doi: 10.1007/s12185-017-2295.
     PubMed     Abstract available
     
     
     
244. HIRANO M, Ohno N, Tanosaki R, Mochizuki M, et al
     Adult T-cell leukemia cell-induced uveitis: rapid increase in adult T-cell leukemia cells disrupts the blood-ocular barrier.
     Int J Hematol. 2017 Jul 4. doi: 10.1007/s12185-017-2293.
     PubMed     Abstract available
     
     
     
245. MIYAZAKI Y
     JSH Guideline for Tumors of Hematopoietic and Lymphoid Tissues: Leukemia: 6. Myelodysplastic syndromes (MDS).
     Int J Hematol. 2017 Jul 4. doi: 10.1007/s12185-017-2272.
     PubMed    
     
     
     
246. UEMURA S, Tamura A, Saito A, Hasegawa D, et al
     Reemergence of translocation t(11;19)(q23;p13.1) in the absence of clinically overt leukemia.
     Int J Hematol. 2017 Jul 1. doi: 10.1007/s12185-017-2289.
     PubMed     Abstract available
     
     
     
247. KUNIMOTO H, Nakajima H
     Epigenetic dysregulation of hematopoietic stem cells and preleukemic state.
     Int J Hematol. 2017;106:34-44.
     PubMed     Abstract available
     
     
     
248. KARIGANE D, Takubo K
     Metabolic regulation of hematopoietic and leukemic stem/progenitor cells under homeostatic and stress conditions.
     Int J Hematol. 2017;106:18-26.
     PubMed     Abstract available
     
     
     
249. MATSUO H, Shiga S, Imai T, Kamikubo Y, et al
     Purification of leukemic blast cells from blood smears using laser microdissection.
     Int J Hematol. 2017;106:55-59.
     PubMed     Abstract available
     
     
     June 2017
250. TANG S, Shen H, Mao X, Dai H, et al
     FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.
     Int J Hematol. 2017 Jun 14. doi: 10.1007/s12185-017-2256.
     PubMed     Abstract available
     
     
     
251. ISHITSUKA K, Yurimoto S, Kawamura K, Tsuji Y, et al
     Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.
     Int J Hematol. 2017 Jun 9. doi: 10.1007/s12185-017-2270.
     PubMed     Abstract available
     
     
     
252. ZHANG R, Chen J, Huang H, Ma J, et al
     Erratum to: Primary fungal prophylaxis in acute leukemia patients with different risk factors: retrospective analysis from the CAESAR study.
     Int J Hematol. 2017 Jun 2. doi: 10.1007/s12185-017-2269.
     PubMed    
     
     
     
253. ITZYKSON R, Duchmann M, Lucas N, Solary E, et al
     CMML: Clinical and molecular aspects.
     Int J Hematol. 2017;105:711-719.
     PubMed     Abstract available
     
     
     May 2017
254. TAMURA A, Uemura S, Saito A, Okubo S, et al
     Congenital immature pure erythroid leukemia with E-cadherin expression.
     Int J Hematol. 2017 May 18. doi: 10.1007/s12185-017-2248.
     PubMed     Abstract available
     
     
     
255. MINAKATA D, Fujiwara SI, Ikeda T, Toda Y, et al
     Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia.
     Int J Hematol. 2017 May 15. doi: 10.1007/s12185-017-2251.
     PubMed     Abstract available
     
     
     
256. HANEKAMP D, Cloos J, Schuurhuis GJ
     Leukemic stem cells: identification and clinical application.
     Int J Hematol. 2017;105:549-557.
     PubMed     Abstract available
     
     
     
257. TAKAGI M, Ishiwata Y, Aoki Y, Miyamoto S, et al
     HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy.
     Int J Hematol. 2017;105:686-691.
     PubMed     Abstract available
     
     
     
258. CAMACHO V, McClearn V, Patel S, Welner RS, et al
     Regulation of normal and leukemic stem cells through cytokine signaling and the microenvironment.
     Int J Hematol. 2017;105:566-577.
     PubMed     Abstract available
     
     
     
259. IKEGAME K, Kaida K, Yoshihara S, Yoshihara K, et al
     Spousal hematopoietic stem cell transplantation.
     Int J Hematol. 2017;105:646-657.
     PubMed     Abstract available
     
     
     
260. URESHINO H, Kizuka H, Kusaba K, Sano H, et al
     5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
     Int J Hematol. 2017;105:692-696.
     PubMed     Abstract available
     
     
     April 2017
261. TOJO A, Kyo T, Yamamoto K, Nakamae H, et al
     Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.
     Int J Hematol. 2017 Apr 25. doi: 10.1007/s12185-017-2238.
     PubMed     Abstract available
     
     
     
262. HATAKE K, Ogura M, Takada K, Taniwaki M, et al
     Ofatumumab combined with chlorambucil for previously untreated chronic lymphocytic leukemia: a phase I/II, open-label study in Japan.
     Int J Hematol. 2017 Apr 18. doi: 10.1007/s12185-017-2233.
     PubMed     Abstract available
     
     
     
263. KE S, Li RC, Lu J, Meng FK, et al
     MicroRNA-192 regulates cell proliferation and cell cycle transition in acute myeloid leukemia via interaction with CCNT2.
     Int J Hematol. 2017 Apr 13. doi: 10.1007/s12185-017-2232.
     PubMed     Abstract available
     
     
     
264. TAKAHASHI N, Nakaseko C, Kobayashi Y, Miyamura K, et al
     Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.
     Int J Hematol. 2017 Apr 13. doi: 10.1007/s12185-017-2239.
     PubMed     Abstract available
     
     
     
265. IGUCHI A, Cho Y, Sugiyama M, Terashita Y, et al
     Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.
     Int J Hematol. 2017 Apr 11. doi: 10.1007/s12185-017-2235.
     PubMed     Abstract available
     
     
     
266. ONG SY, Ho LP, Yeo PM, Ng HJ, et al
     Marked hypereosinophilia and rash as initial presentation of acute myeloid leukemia with t(8;21).
     Int J Hematol. 2017 Apr 7. doi: 10.1007/s12185-017-2230.
     PubMed    
     
     
     
267. ZHANG R, Chen J, Huang H, Ma J, et al
     Primary fungal prophylaxis in acute leukemia patients with different risk factors: retrospective analysis from the CAESAR study.
     Int J Hematol. 2017 Apr 7. doi: 10.1007/s12185-017-2224.
     PubMed     Abstract available
     
     
     
268. SUH KJ, Lee JY, Shin DY, Koh Y, et al
     Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.
     Int J Hematol. 2017 Apr 4. doi: 10.1007/s12185-017-2225.
     PubMed     Abstract available
     
     
     
269. YAGUCHI A, Ishibashi T, Terada K, Ueno-Yokohata H, et al
     EP300-ZNF384 fusion gene product up-regulates GATA3 gene expression and induces hematopoietic stem cell gene expression signature in B-cell precursor acute lymphoblastic leukemia cells.
     Int J Hematol. 2017 Apr 4. doi: 10.1007/s12185-017-2220.
     PubMed     Abstract available
     
     
     
270. ASANO M, Umezu T, Katagiri S, Kobayashi C, et al
     Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors.
     Int J Hematol. 2017;105:419-422.
     PubMed     Abstract available
     
     
     March 2017
271. NAKAMAE H, Fujisawa S, Ogura M, Uchida T, et al
     Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report.
     Int J Hematol. 2017 Mar 24. doi: 10.1007/s12185-017-2208.
     PubMed     Abstract available
     
     
     
272. BARAKA A, Sherief LM, Kamal NM, Shorbagy SE, et al
     Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
     Int J Hematol. 2017 Mar 21. doi: 10.1007/s12185-017-2206.
     PubMed     Abstract available
     
     
     
273. KATZ BZ, Herishanu Y
     Fragility of sub-cellular structures in chronic lymphocytic leukemia.
     Int J Hematol. 2017 Mar 21. doi: 10.1007/s12185-017-2218.
     PubMed    
     
     
     
274. LOVATO S, Ayto R
     Haemolysis in female patient with chronic phase CML.
     Int J Hematol. 2017;105:233-234.
     PubMed    
     
     
     
275. KANAMITSU K, Shimada A, Nishiuchi R, Shigemura T, et al
     Pediatric intestinal Behcet disease complicated by myeloid malignancies.
     Int J Hematol. 2017;105:377-382.
     PubMed     Abstract available
     
     
     January 2017
276. WAISBREN J, Dinner S, Altman J, Frankfurt O, et al
     Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
     Int J Hematol. 2017;105:44-51.
     PubMed     Abstract available
     
     
     November 2016
277. UEMURA M, Imataki O, Kawachi Y, Kawakami K, et al
     Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor.
     Int J Hematol. 2016;104:621-627.
     PubMed     Abstract available
     
     
     
278. JUNG KS, Cho SH, Kim SJ, Ko YH, et al
     Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma.
     Int J Hematol. 2016;104:591-595.
     PubMed     Abstract available
     
     
     
279. RUBIO P, Campos B, Digiorge JA, Gallego MS, et al
     NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
     Int J Hematol. 2016;104:582-590.
     PubMed     Abstract available
     
     
     
280. MONIKA BELICKOVA M, Merkerova MD, Votavova H, Valka J, et al
     Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms.
     Int J Hematol. 2016;104:566-573.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: